Expanded Access Program (EAP): Allow Patients in the US With Idiopathic Pulmonary Fibrosis Access to Pirfenidone

Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT00662038 ·Status: COMPLETED ·Phase: PHASE3

Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis

NCT00080223 ·Status: COMPLETED ·Phase: PHASE2

Management of Progressive Disease in Idiopathic Pulmonary Fibrosis

NCT03939520 ·Status: COMPLETED ·Phase: PHASE4

Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

NCT00287716 ·Status: COMPLETED ·Phase: PHASE3

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)

NCT05321069 ·Status: COMPLETED ·Phase: PHASE3

Supporting Adherence to Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

NCT03567785 ·Status: COMPLETED

A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)

NCT05321082 ·Status: COMPLETED ·Phase: PHASE3

Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT02699879 ·Status: COMPLETED

Pilot Study of Pirfenidone in Pulmonary Fibrosis With Anti-myeloperoxydase Antibodies

NCT03385668 ·Status: COMPLETED ·Phase: PHASE2

Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF)

NCT01504334 ·Status: UNKNOWN ·Phase: PHASE2

Safety, Tolerability and PK of Nintedanib in Combination With Pirfenidone in IPF

NCT02579603 ·Status: COMPLETED ·Phase: PHASE4

A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT02707640 ·Status: COMPLETED ·Phase: PHASE2

Study of Efficacy and Safety of Pirfenidone in Patients With Fibrotic Hypersensitivity Pneumonitis

NCT02958917 ·Status: TERMINATED ·Phase: PHASE2

A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

NCT02648048 ·Status: COMPLETED ·Phase: PHASE1

Safety and Tolerability Study of Pirfenidone in Combination With Nintedanib in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT02598193 ·Status: COMPLETED ·Phase: PHASE4

Pirfenidone Compared to Placebo in Post-COVID19 Pulmonary Fibrosis COVID-19

NCT04607928 ·Status: UNKNOWN ·Phase: PHASE2

Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis

NCT01262001 ·Status: COMPLETED ·Phase: PHASE2

Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis

NCT02136992 ·Status: COMPLETED ·Phase: PHASE2

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT05571059 ·Status: RECRUITING ·Phase: PHASE2

A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF)

NCT01872689 ·Status: COMPLETED ·Phase: PHASE2

A Trial to Evaluate the Efficacy of PRM-151 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

NCT02550873 ·Status: COMPLETED ·Phase: PHASE2

Pirfenidone in the Chronic Hypersensitivity Pneumonitis Treatment

NCT02496182 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3

This Study Tests Different Doses of BI 1015550 in Patients With Idiopathic Pulmonary Fibrosis (IPF). The Study Tests How BI 1015550 is Taken up by the Body and How Well it is Tolerated.

NCT03422068 ·Status: COMPLETED ·Phase: PHASE1

Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF)

NCT01366209 ·Status: COMPLETED ·Phase: PHASE3

Treatment of Idiopathic Pulmonary Fibrosis with Long Acting Octreotide

NCT00463983 ·Status: COMPLETED ·Phase: PHASE1/PHASE2